FDA Must Lift "Limbo" Over Trials In Supplement Development - Caucus
FDA should move dietary supplement firms out of "limbo" when it comes to the rules for using scientific studies in developing new products, industry supporters in the House say
FDA should move dietary supplement firms out of "limbo" when it comes to the rules for using scientific studies in developing new products, industry supporters in the House say